Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease

Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide,...

Full description

Saved in:
Bibliographic Details
Main Authors GEWITZ, ANDREW T, ROBACK, JOHN D, WALLER, EDMUND K, HOSSAIN, MOHAMMAD S
Format Patent
LanguageEnglish
Published 15.01.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject.
Bibliography:Application Number: AU20090298122